Skip to content

Depression research published in 2023

Page 5 of 24: studies 81 to 100 of 466, newest first. Back to the depression overview

Studies

How psychedelic-assisted therapy works for depression: expert views and practical implications from an exploratory Delphi study.

Frontiers in Psychiatry September 28, 2023 Lauren Johansen, Paul Liknaitzky, Maja Nedeljkovic et al. 5 citations

As investigations into the efficacy of psychedelic-assisted psychotherapy to treat depression continue, there is a need to study the possible mechanisms of action that may contribute to the treatment's antidepressant effects. Through a two-round Delphi design, the current study investigated experts' opinions on the psychological mechanisms of action associated with the antidepressant effects of...

DOI: 10.3389/fpsyt.2023.1265910 (opens in new tab) Full text (opens in new tab) Psychedelic therapy Mental health treatment Depression research Therapeutic mechanisms +1

Depression and Anxiety among Gay and Bisexual Men: Testing a Mediated Moderation Model of Mindfulness and Adult Attachment

Sexes September 27, 2023 K. Marie Sizemore, Shannon S. Gray, Steven Samrock et al. 4 citations

For sexual minority men (SMM), attachment anxiety and attachment avoidance are evidenced to predict poor mental health (e.g., depression and anxiety). While mindfulness is known to mediate this relationship among the general population, it has yet to be examined among SMM. This study examined the interaction of attachment anxiety and avoidance, and the mediating effect of mindfulness, in...

(S)-Ketamine but Not (R)-Ketamine Shows Acute Effects on Depression-Like Behavior and Sleep-Wake Architecture in Rats

The International Journal of Neuropsychopharmacology September 25, 2023 Szabolcs Koncz, Noémi Papp, Dóra Pothorszki et al. 29 citations

Abstract Background Racemic ketamine consists of two enantiomers, namely (R)-ketamine and (S)-ketamine, with distinguishable pharmacological properties. Both enantiomers have been reported to show rapid antidepressant effects in rodents. Currently, the (S)-enantiomer has been approved for the treatment of major depression, whereas (R)-ketamine failed to show antidepressant effect in recent...

INVESTIGATION OF THE RELATIONSHIP OF YOGA TRANSFORMATION EFFECT ON LEVELS OF DEPRESSION, ANXIETY, STRESS AND MINDFULNES IN INDIVIDUALS PLAYING YOGA

The Online Journal of Recreation and Sport September 23, 2023 Büşra Erul, Ülviye Bilgin, Emre Bağcı

Nowadays, it is seen that individuals often do yoga as a way to improve their physical and psychological health with the pursuit of feeling good. In this study, it was aimed to examine the relationship of yoga transformation effect on depression, anxiety, stress and mindfulnes (Conscious Awareness) in individuals who practice yoga. A total of 236 subjects voluntarily participated in the study,...

Technology-Enabled Intervention to Enhance Mindfulness, Safety, and Health Promotion Among Corrections Professionals: Protocol for a Prospective Quasi-Experimental Trial.

JMIR Research Protocols September 22, 2023 Diane Elliot, Kerry Kuehl, Carol DeFrancesco et al.

Background: Correction professionals are a highly stressed workforce with heightened risks for depression, suicide, obesity, cardiovascular disease, and injury. These professionals, largely hidden from view, have received little study concerning means to improve their safety, health, and well-being. In other settings, mindfulness has resulted in lowered stress, along with other benefits. We...

Reducing anxiety and depression symptoms in pregnancy: Case report of maternal mental health from Indonesia

Jurnal Aisyah Jurnal Ilmu Kesehatan September 22, 2023 Dewi Nirmala Sari, Safrudin Safrudin, Mardeyanti Mardeyanti et al.

Mental health is neglected in antenatal care in Low- and Middle-Income Countries, whereas the prevalence of anxiety and depression symptoms in pregnant women is increasing yearly. Mindfulness is a new recommended method to prevent and reduce symptoms of anxiety and depression, but it is still rarely practised in Indonesia. This case report aimed to explore mindfulness-based interventions...

Use of ketamine for reversing acute depression in a critically ill pretransplant patient

JHLT Open September 22, 2023 Anna Bovill Shapiro, Mohit Chauhan, Archer Kilbourne Martin et al. 1 citation

A 68-year-old with a history of ischemic cardiomyopathy, chronic kidney disease, hypertension, and anxiety was admitted to the intensive care unit (ICU) in cardiogenic shock. After an intubation and several days in the ICU, he expressed hopelessness with further care and was considering a transition to hospice. The treatment team was concerned that clinical depression was influencing his...

An empirical investigation of the associations between metacognition, mindfulness experiential avoidance, depression, and anxiety

BMC Psychology September 21, 2023 Torstein Ådnøy, Stian Solem, Roger Hagen et al.

Abstract Background The aims of this study were to explore the possible relation between metacognition, mindfulness, and experiential avoidance, as well as their association with symptoms of anxiety and depression. Methods Cross-sectional data was collected from a community sample (N = 364) who completed the Metacognitions Questionnaire-30 (MCQ-30), the Five Facet Mindfulness Questionnaire-24...

Early effects predict trajectories of response to esketamine in treatment-resistant depression.

Journal of Affective Disorders September 20, 2023 Isaure Estrade, Anne-Cécile Petit, Vincent Sylvestre et al.

Background: The efficacy of esketamine in treatment-resistant depression (TRD) has been confirmed. However, its administration is expensive and restrictive, with limited knowledge on how long the treatment should be continued. Predicting the treatment outcome would benefit patients and alleviate the global treatment cost. We aimed to define distinct trajectories of treatment response and assess...

Ketamine: Mechanisms and Relevance to Treatment of Depression.

Annual Review of Medicine September 20, 2023 Ji-Woon Kim, Kanzo Suzuki, Ege T Kavalali et al. 105 citations

Major depressive disorder (MDD) is a leading cause of suicide in the world. Monoamine-based antidepressant drugs are a primary line of treatment for this mental disorder, although the delayed response and incomplete efficacy in some patients highlight the need for improved therapeutic approaches. Over the past two decades, ketamine has shown rapid onset with sustained (up to several days)...

Administration of oxathridine, a first‐in‐class histamine‐3 receptor partial agonist in healthy male volunteers: Central nervous system depression and pseudo‐hallucinations

British Journal of Clinical Pharmacology September 19, 2023 Francis M. Dijkstra, Rob G J A Zuiker, Jules A A C Heuberger et al. 1 citation

AIMS: To characterise the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of single ascending doses of oxathridine, a first-in-class histamine-3 receptor partialagonist, in healthy male volunteers. METHODS: A randomised, double-blind, placebo-controlled study including the NeuroCart, consisting of a battery of drug sensitive neurophysiological tests, was performed....

Medicalisation of Ayahuasca as a Depression Treatment

The Maastricht Journal of Liberal Arts September 19, 2023 Elena Gomel Cordeiro

This paper examines the possible consequences of medicalising the psychedelic Ayahuasca to be used as a treatment for depression. Through a science and technology studies (STS) understanding of the social construction of scientific facts, I consider how traditional indigenous uses of Ayahuasca are translated into Western medicine. Two special points of attention are: (1) the cultural...

DOI: 10.26481/mjla.2023.v14.912 (opens in new tab) Ayahuasca Indigenous Biomedicine Medicalization +7

The Montreal model: an integrative biomedical-psychedelic approach to ketamine for severe treatment-resistant depression

Frontiers in Psychiatry September 19, 2023 Nicolas Garel, Jessica Drury, Julien Thibault Lévesque et al. 32 citations

Background Subanesthetic ketamine has accumulated meta-analytic evidence for rapid antidepressant effects in treatment-resistant depression (TRD), resulting in both excitement and debate. Many unanswered questions surround ketamine’s mechanisms of action and its integration into real-world psychiatric care, resulting in diverse utilizations that variously resemble electroconvulsive therapy,...

DOI: 10.3389/fpsyt.2023.1268832 (opens in new tab) Ketamine Biopsychosocial model Psychotherapist Clinical psychology

The not so little matter of how to dose ketamine in patients with depression

Acta Psychiatrica Scandinavica September 17, 2023 Chittaranjan Andrade 5 citations

It is almost axiomatic with most drugs and for most disorders in psychiatry that whatever elicits response and remission during the acute phase of illness will prevent relapse and recurrence of illness during the maintenance phase of treatment. Logically, this principle should apply to ketamine, as well, when the drug is used for patients with depression; thus, at the very least, the treatment,...

Propofol for treatment resistant depression: A randomized controlled trial

medRxiv September 15, 2023 Scott C. Tadler, Keith Jones, Carter Lybbert et al. 7 citations preprint

Background: Anesthetic agents including ketamine and nitrous oxide have shown antidepressant properties when appropriately dosed. Our recent open-label trial of propofol, an intravenous anesthetic known to elicit transient positive mood effects, suggested that it may also produce robust and durable antidepressant effects when administered at a high dose that elicits an electroencephalographic...

The psychedelic experience and treatment‐resistant depression

World Psychiatry September 15, 2023 Guy M. Goodwin

Interest in the use of serotonergic agonists such as psilocybin in treatment-resistant depression (TRD) has grown more quickly than the evidence on which to base a final opinion, as emphasized by McIntyre et al1 in their review. Psilocybin, once metabolized to psilocin, activates 5-HT2A receptors, enhancing GABA function in local circuits in the cortex and increasing connectivity between...

Using mindfulness-based stress reduction to relieve loneliness, anxiety, and depression in cancer patients: A systematic review and meta-analysis.

Medicine September 15, 2023 Junye Yu, Mingyue Han, Fengru Miao et al. 26 citations

Mindfulness-based stress reduction (MBSR) has been suggested as an effective mind-body approach for relieving stress in patients with chronic diseases. As of yet, there is no conclusive research on MBSR's role in reducing affective disorders among cancer patients. A systematic review and meta-analysis was conducted to determine whether MBSR has an impact on loneliness, anxiety, and depression...

Psychoactive substances 25H-NBOMe and 25H-NBOH induce antidepressant-like behavior in male rats.

European Journal of Pharmacology September 15, 2023 Barbara G Ferri, Cintia O De Novais, Raquel S Bonani et al. 11 citations

Ring-substituted phenethylamines are believed to induce psychedelic effects primarily by interacting with 5-hydroxytryptamine 2 (5-HT2A) receptors in the brain. We assessed the effect of the psychedelic substances 25H-NBOMe and 25H-NBOH on the depressive-like behavior of male adult rats. Naive Wistar rats were divided into groups to assess the effects of different doses (0.1 mg/kg, 1 mg/kg, and...